VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Breakthrough Therapy for Special CRC Subtype: JMT101 + Irinotecan Achieves 47.1% ORR
Breakthrough Therapy for Special CRC Subtype: JMT101 + Irinotecan Achieves 47.1% ORR
Jun 04, 2026 01:45 CST Updated 13:27
Share:
